John Berrios, Bayer US SVP and general manager of women’s healthcare

Bay­er gets FDA nod to ex­tend use of pop­u­lar con­tra­cep­tive IUD Mire­na

Now more than ever, it’s im­por­tant for women to have op­tions when it comes to con­tra­cep­tion, said Bay­er’s se­nior VP and gen­er­al man­ag­er of women’s health­care John Berrios. The phar­ma gi­ant’s lat­est ap­proval for its pop­u­lar IUD prod­uct Mire­na should help with that.

Mire­na scored an ap­proval on Thurs­day to pre­vent preg­nan­cy for up to eight years, ex­tend­ing its use by one year. Reg­u­la­tors based their de­ci­sion on a Phase III ex­ten­sion tri­al show­ing Mire­na main­tained its ef­fi­ca­cy of greater than 99% dur­ing years 6 through 8, while ex­hibit­ing no new or un­ex­pect­ed safe­ty risks. It’s al­so ap­proved to treat heavy pe­ri­ods for up to five years.

The move comes as more than a dozen states have banned abor­tions fol­low­ing the Dobbs v. Jack­son Women’s Health Or­ga­ni­za­tion de­ci­sion, and a hand­ful of oth­ers seek to do the same.

“As a com­pa­ny, we do not sup­port any steps that take away con­tra­cep­tive choic­es, and we tru­ly do op­pose any ef­forts that lim­it those health­care op­tions,” Berrios said. “We are for her and we’re go­ing to con­tin­ue to be, like we have been for the last 61 years.”

Mire­na is a hor­mone-re­leas­ing IUD, which is in­sert­ed in­to the uterus dur­ing a clin­ic vis­it. It was first ap­proved back in 2000 to pre­vent preg­nan­cies for up to five years, and the ap­proval for sev­en-year use came last sum­mer. The com­pa­ny al­so has Kyleena, its low-dose T-shaped de­vice ap­proved back in 2016 to pre­vent preg­nan­cy for up to five years.

“Hav­ing that eight-year in­di­ca­tion we re­al­ly be­lieve gives women what they’re look­ing for in re­gards to long-act­ing birth con­trol,” Berrios said.

Bay­er was the first phar­ma to se­cure FDA ap­proval for an oral birth con­trol pill in 1960. In 2020, the com­pa­ny launched its “We’re For Her” cam­paign to ex­pand ac­cess to con­tra­cep­tion, with the hopes of reach­ing 100 mil­lion women by 2030.

“Over the last few months, with a lot of things in the press, there’s been a lot more peo­ple look­ing and search­ing for op­tions for birth con­trol. And we be­lieve that the amount of women look­ing for in­for­ma­tion has grown,” Berrios said. “Have we seen a sig­nif­i­cant in­crease in uti­liza­tion at this point? No. But I think this is a point where women are re­al­ly seek­ing op­tions and that’s our job, is to get the op­tions out.”

Look­ing ahead, the com­pa­ny is putting more em­pha­sis on so­cial me­dia cam­paigns, Berrios said, in­clud­ing through work with mi­cro-in­flu­encers.

“We re­al­ly want to be where peo­ple are and where they’re seek­ing in­for­ma­tion,” he said.

Am­gen lays off about 300 work­ers, cit­ing 'in­dus­try head­wind­s'

Amgen has laid off about 300 employees, a company spokesperson confirmed to Endpoints News via email Sunday night.

Employees posted to LinkedIn in recent days about layoffs hitting Amgen last week. The Thousand Oaks, CA-based biopharma, which employs about 24,000 people, said the reduction “mainly” impacted US-based workers on its commercial team.

Drug developers of all sizes, including small upstarts and pharma giants, have let employees go in recent months as the biopharma market drags through a quarters-long winter doldrum.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Bob Bradway, Amgen CEO (Stephen Lam/Reuters)

Am­gen launch­es the first US Hu­mi­ra biosim­i­lar at two dif­fer­ent list prices

The bizarre dynamics of the US prescription drug market were on full display once again this morning as Amgen announced that it would launch the first US biosimilar for Humira, the best-selling drug of all time, at two completely different list prices.

One price for Amgen’s Amjevita (adalimumab-atto) will be 55% below the current Humira list price, which is about $84,000 per year, and another at a list price 5% below the current Humira list price, but presumably (pharma companies don’t disclose rebates) with high rebates to attract PBMs and payers.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.

Boehringer In­gel­heim touts pre­ven­tion re­sults in rarest form of pso­ri­a­sis

Boehringer Ingelheim uncorked some positive results suggesting that Spevigo can help prevent flare-ups in patients with a severe form of psoriasis, months after the drug was approved to treat existing flares.

Spevigo, an IL-36R antibody also known as spesolimab, met its primary and a key secondary endpoint in the Phase IIb EFFISAYIL 2 trial in patients with generalized pustular psoriasis (GPP), Boehringer announced on Monday. While the company is keeping the hard numbers under wraps until later this year, it said in a news release that it anticipates sharing the results with regulators.

As­traZeneca, No­vo Nordisk and Sanofi score 340B-re­lat­ed ap­peals court win over HHS

AstraZeneca, Novo Nordisk, and Sanofi won an appeals court win on Monday, as the US Court of Appeals for the Third Circuit found that the companies cannot be forced to provide 340B-discounted drugs purchased by hospitals from an unlimited number of community and specialty pharmacies.

“Legal duties do not spring from silence,” the decision says as the court makes clear that the federal government’s interpretation of the “supposed requirement” that the 340B program compels drugmakers to supply their discounted drugs to an unlimited number of contract pharmacies is not correct, noting:

Ap­peals court toss­es J&J's con­tro­ver­sial 'Texas two-step' bank­rupt­cy case

A US appeals court has ruled against Johnson & Johnson’s use of bankruptcy to deal with mounting talc lawsuits, deciding that doing so would “create a legal blind spot.”

The Third Circuit Court of Appeals reversed a previous bankruptcy court decision on Monday, calling for the dismissal of a Chapter 11 filing by J&J’s subsidiary LTL Management.

Faced with more than 38,000 lawsuits alleging its talc-based products caused cancer, J&J spun its talc liabilities into a separate company called LTL Management back in October 2021 and filed for bankruptcy, a controversial move colloquially referred to as a “Texas two-step” bankruptcy. Claimants argued that the strategy is a misuse of the US bankruptcy code — and on Monday, a panel of judges agreed.

Credit: Shutterstock

New York City in­vests $20M in­to biotech 'in­no­va­tion space' at the Brook­lyn Navy Yard

New York City is investing $20 million in biotech this year in the form of a 50,000-square-foot “innovation space” at the Brooklyn Navy Yard, complete with offices, research laboratories and events and programming space to grow biotech startups and companies.

Mayor Eric Adams said during his State of The City Address last Thursday that there will be an “emphasis” on making more opportunities for women and people of color to further diversify the industry. The City first reported the news.

Dirk Thye, Quince Therapeutics CEO

Af­ter piv­ot­ing from Alzheimer's to bone con­di­tions, biotech piv­ots again — and halves its head­count

When troubled public biotech Cortexyme bought a private startup named Novosteo and handed the keys to its executive team, the company — which changed its name to Quince Therapeutics — said it would shift its focus from an unorthodox Alzheimer’s approach to Novosteo’s bone-targeting drug platform.

Less than a year later, Quince is pivoting again.

The biotech has decided to out-license its bone-targeting drug platform and its lead drug, NOV004, and instead look for clinical-stage programs to in-license or acquire, according to a press release.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.

Troy Tazbaz, FDA's newly-named director of the Digital Health Center of Excellence (Oracle via YouTube)

Or­a­cle ex­ec­u­tive Troy Tazbaz named new FDA di­rec­tor of dig­i­tal health

The FDA has found a brand new director of the Digital Health Center of Excellence in Troy Tazbaz, a former senior vice president at Oracle.

According to Tazbaz’s LinkedIn, he took a five-month break after leaving an 11-year career at Oracle before joining the FDA in January. Stat News first reported the hire. Tazbaz also said on his LinkedIn that he biked all the way from Chesapeake Bay to the San Francisco Bay over 58 days during his career break.

Richard Gonzalez, AbbVie CEO (Chris Kleponis/picture-alliance/dpa/AP Images)

Up­dat­ed: $100B+ in sav­ings? Why the in­com­ing Hu­mi­ra biosim­i­lars will take time to catch on

The 20-year reign of AbbVie’s best-selling biologic of all time — the autoimmune disease biologic Humira (adalimumab) that has brought in upwards of $200 billion during its monopoly — is coming to an end tomorrow with the launch of Amgen’s biosimilar Amjevita.

The launch comes more than four years after Europe saw the exact same competition, leading to steep discounts in price, higher uptake, and big cost savings across the board.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.